journal article·2024-08Open access

A Glucose‐Responsive Hydrogel Inhibits Primary and Secondary BRB Injury for Retinal Microenvironment Remodeling in Diabetic Retinopathy

Yue Zhou, Chan Zhao, Zhiyuan Shi, Zbynek Heger, HuaQing Jing, Zhengming Shi, Yunsheng Dou, Siyu Wang, Zitong Qiu, Nan Li

Advanced Science· Volume 11· Issue 32

Abstract

Abstract Current diabetic retinopathy (DR) treatment involves blood glucose regulation combined with laser photocoagulation or intravitreal injection of vascular endothelial growth factor (VEGF) antibodies. However, due to the complex pathogenesis and cross‐interference of multiple biochemical pathways, these interventions cannot block disease progression. Recognizing the critical role of the retinal microenvironment (RME) in DR, it is hypothesized that reshaping the RME by simultaneously inhibiting primary and secondary blood–retinal barrier (BRB) injury can attenuate DR. For this, a glucose‐responsive hydrogel named Cu‐PEI/siMyD88@GEMA‐Con A (CSGC) is developed that effectively delivers Cu‐PEI/siMyD88 nanoparticles (NPs) to the retinal pigment epithelium (RPE). The Cu‐PEI NPs act as antioxidant enzymes, scavenging ROS and inhibiting RPE pyroptosis, ultimately blocking primary BRB injury by reducing microglial activation and Th1 differentiation. Simultaneously, MyD88 expression silence in combination with the Cu‐PEI NPs decreases IL‐18 production, synergistically reduces VEGF levels, and enhances tight junction proteins expression, thus blocking secondary BRB injury. In summary, via remodeling the RME, the CSGC hydrogel has the potential to disrupt the detrimental cycle of cross‐interference between primary and secondary BRB injury, providing a promising therapeutic strategy for DR.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Retinal Diseases and Treatments · Heme Oxygenase-1 and Carbon Monoxide · Advanced Glycation End Products research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Tianjin Key Laboratory of Drug Delivery & High‐Efficiency School of Pharmaceutical Science and Technology Tianjin University Tianjin 300072 P. R. China

Department of Pharmacy Tianjin Union Medical Center Nankai University Tianjin 300122 P. R. China

Department of Ophthalmology Peking Union Medical College Hospital Chinese Academy of Medical Sciences Beijing 100730 P. R. China

Key Laboratory of Ocular Fundus Diseases Chinese Academy of Medical Sciences & Peking Union Medical College Beijing 100730 P. R. China

Department of Chemistry and Biochemistry Mendel University in Brno Brno CZ‐61300 Czech Republic

Funding

Natural Science Foundation of Tianjin Municipality · National Natural Science Foundation of China

References (45)

Show source-provided references
1. 10.1016/S2214-109X(13)70113-X10.1016/S2214-109X(13)70113-X ↗
2. 10.1016/j.preteyeres.2013.02.00110.1016/j.preteyeres.2013.02.001 ↗
3. 10.3390/ijms1906180610.3390/ijms19061806 ↗
4. 10.4239/wjd.v12.i9.144210.4239/wjd.v12.i9.1442 ↗
5. 10.1016/j.ophtha.2015.03.02410.1016/j.ophtha.2015.03.024 ↗
6. 10.1007/s44194-023-00021-610.1007/s44194-023-00021-6 ↗
7. 10.1016/j.preteyeres.2019.10077810.1016/j.preteyeres.2019.100778 ↗
8. 10.3390/ijms1904105610.3390/ijms19041056 ↗
9. 10.3390/ijms2410879610.3390/ijms24108796 ↗
10. 10.1016/j.survophthal.2022.07.00810.1016/j.survophthal.2022.07.008 ↗
11. 10.1097/CM9.000000000000101510.1097/CM9.0000000000001015 ↗
12. 10.1016/j.mvr.2013.06.00710.1016/j.mvr.2013.06.007 ↗
13. 10.1007/s10456-007-9067-z10.1007/s10456-007-9067-z ↗
14. 10.1016/j.visres.2017.05.00910.1016/j.visres.2017.05.009 ↗
15. 10.1016/j.bbi.2012.10.01410.1016/j.bbi.2012.10.014 ↗
16. 10.3389/fimmu.2012.0028810.3389/fimmu.2012.00288 ↗
17. 10.1111/imr.1229610.1111/imr.12296 ↗
18. 10.1038/srep2063910.1038/srep20639 ↗
19. 10.1186/s12974-018-1062-310.1186/s12974-018-1062-3 ↗
20. 10.1016/j.cell.2012.03.03610.1016/j.cell.2012.03.036 ↗
21. 10.1038/nature0966310.1038/nature09663 ↗
22. 10.1080/08923973.2020.180898610.1080/08923973.2020.1808986 ↗
23. Ozaki E. · J. Inflamm. Res. · 2015 · 8 · 15
24. 10.4049/jimmunol.120310310.4049/jimmunol.1203103 ↗
25. 10.1016/j.bbrc.2017.08.08510.1016/j.bbrc.2017.08.085 ↗
26. 10.2337/db07-098210.2337/db07-0982 ↗
27. 10.1186/2045-3701-4-2710.1186/2045-3701-4-27 ↗
28. 10.1016/j.bios.2004.10.00210.1016/j.bios.2004.10.002 ↗
29. 10.1201/978142004118710.1201/9781420041187 ↗
30. 10.1371/journal.pone.002332210.1371/journal.pone.0023322 ↗
31. 10.1007/s00441-005-0046-710.1007/s00441-005-0046-7 ↗
32. 10.1111/cea.1216510.1111/cea.12165 ↗
33. 10.1016/j.biopha.2017.02.08110.1016/j.biopha.2017.02.081 ↗
34. 10.1089/jop.2019.001710.1089/jop.2019.0017 ↗
35. 10.1248/bpb.b17-0047510.1248/bpb.b17-00475 ↗
36. 10.3390/ijms2003064910.3390/ijms20030649 ↗
37. 10.1016/j.immuni.2013.08.00110.1016/j.immuni.2013.08.001 ↗
38. 10.1073/pnas.172204111510.1073/pnas.1722041115 ↗
39. 10.1016/j.biopha.2020.10992410.1016/j.biopha.2020.109924 ↗
40. 10.1016/j.jneuroim.2010.09.02510.1016/j.jneuroim.2010.09.025 ↗
41. 10.1016/j.pneurobio.2018.05.00610.1016/j.pneurobio.2018.05.006 ↗
42. 10.1186/2047-9158-1-910.1186/2047-9158-1-9 ↗
43. 10.1016/j.ajo.2008.05.03210.1016/j.ajo.2008.05.032 ↗
44. 10.3390/pharmaceutics1305064710.3390/pharmaceutics13050647 ↗
45. 10.1038/s41467-023-38056-w10.1038/s41467-023-38056-w ↗